局部胰腺癌多药化疗联合或不联合放疗后切缘阴性切除与病理降期的国家癌症数据库分析
该研究基于美国国家癌症数据库2006至2016年接受术前多药化疗(MAC)或MAC联合放疗(MAC+RT)后行肿瘤切除的非转移性胰腺导管腺癌(PDAC)患者,比较两组R0切除率与病理应答。结果显示MAC+RT组R0切除率86%高于MAC组80%(p<0.001),病理完全应答率5%高于2%(p<0.001),多因素分析中MAC+RT与更高R0切除几率相关(OR 1.58,95%CI 1.33-1.89,p<0.001)。
要点
- 术前MAC+RT较单纯MAC与更高R0切除率相关(86% vs 80%,p<0.001)。
- MAC+RT组病理完全应答率更高(5% vs 2%,p<0.001),ypN+更低(32% vs 55%)。
- 多因素分析MAC+RT与R0切除几率升高独立相关(OR 1.58,95%CI 1.33-1.89)。
核心结论
- 对于接受术前MAC的局部PDAC患者,加用术前RT与R0切除率和病理应答改善相关。
研究设计与样本
- 基于美国国家癌症数据库2006至2016年非转移性PDAC接受术前MAC或MAC+RT后行肿瘤切除患者的回顾性队列分析。
- 共纳入4599例患者,其中MAC组3109例,MAC+RT组1490例。
- 采用logistic回归分析R0切除相关因素,Kaplan Meier法和Cox回归分析生存。
主要发现
- MAC+RT组较MAC组更多为cT3-4期(76% vs 64%,p<0.001)和cN+期(33% vs 29%,p=0.010)。
- MAC+RT组较MAC组更少为ypT3-4期(59% vs 74%,p<0.001)和ypN+期(32% vs 55%,p<0.001)。
- MAC+RT组病理完全应答率5%高于MAC组2%(p<0.001),R0切除率86%高于80%(p<0.001)。
- 多因素分析中MAC+RT(OR 1.58,95%CI 1.33-1.89,p<0.001)、学术中心评估(OR 1.33,95%CI 1.14-1.56,p<0.001)和女性(OR 1.43,95%CI 1.23-1.67,p<0.001)与更高R0切除几率相关。
- 多因素分析中cT3-4期与更低R0切除几率相关(OR 0.81,95%CI 0.68-0.96,p=0.013)。
关键数值与推荐
- R0切除率:MAC+RT组86%,MAC组80%(p<0.001)。
- 病理完全应答率:MAC+RT组5%,MAC组2%(p<0.001)。
- MAC+RT与R0切除的OR为1.58(95%CI 1.33-1.89,p<0.001)。
- 学术中心评估与R0切除的OR为1.33(95%CI 1.14-1.56,p<0.001)。
- 女性与R0切除的OR为1.43(95%CI 1.23-1.67,p<0.001),cT3-4期OR为0.81(95%CI 0.68-0.96,p=0.013)。
临床怎么用
- 在局部PDAC术前多药化疗基础上加用放疗可能提高R0切除率和病理应答,支持个体化考虑术前放疗。
局限性
- 原文未报告生存分析结果的具体数值。
- 本研究为回顾性数据库分析,原文未报告其局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Margin-negative (R0) resection is the only potentially curative treatment for patients with pancreatic ductal adenocarcinoma (PDAC). Pre-operative multi-agent chemotherapy alone (MAC) or MAC followed by pre-operative radiotherapy (MAC + RT) may be used to improve resectability and potentially survival. However, the optimal pre-operative regimen is unknown. METHODS: Patients with non-metastatic PDAC from 2006 to 2016 who received pre-operative MAC or MAC + RT before oncologic resection were identified in the National Cancer Database. Univariable and multivariable (MVA) associates with R0 resection were identified with logistic regression, and survival was analyzed secondarily with the Kaplan Meier method and Cox regression analysis. RESULTS: 4,599 patients were identified (MAC: 3,109, MAC + RT: 1,490). Compared to those receiving MAC, patients receiving MAC + RT were more likely to have cT3-4 disease (76% vs 64%, p < 0.001) and cN + disease (33% vs 29%, p = 0.010), but were less likely to have ypT3-4 disease (59% vs 74%, p < 0.001) and ypN + disease (32% vs 55%, p < 0.001) and more likely to have a pathologic complete response (5% vs 2%, p < 0.001) and R0 resection (86% vs 80%, p < 0.001). On MVA, MAC + RT (OR 1.58, 95% CI 1.33-1.89, p < 0.001), evaluation at an academic center (OR 1.33, 95% CI 1.14-1.56, p < 0.001), and female sex (OR 1.43, 95% CI 1.23-1.67, p < 0.001) were associated with higher odds of R0 resection, while cT3-4 disease (OR 0.81, 95% CI 0.68-0.96, p = 0.013) was associated with lower odds of R0 resection. CONCLUSION: For patients with localized PDAC who receive pre-operative MAC, the addition of pre-operative RT was associated with improved rates of R0 resection and pathologic response.
引用
- Miccio JA, Talcott WJ, Patel T, et al. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clin Transl Radiat Oncol. 2020. PMID: 33392398. doi:10.1016/j.ctro.2020.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。